When quality breaks down in a clinical trial, the cost isn’t limited to rework. It can slow enrollment, delay regulatory submissions, strain site relationships, and ultimately postpone getting treatments to the patients who need them.
This is why quality is not simply a compliance exercise; it is a strategic performance driver. The organizations that “design quality in” early are the ones that avoid costly disruptions later.
Recent industry analyses, including updated Tufts CSDD research, show a consistent pattern:
While costs vary by therapeutic area and study complexity, current benchmark data indicates:
The financial cost is only part of the loss. Each amendment also risks confidence, continuity, and data coherence — especially when changes occur late.
Organizations with Quality by Design (QbD) and Risk-Based Quality Management (RBQM) practices perform differently:
This aligns directly with the expectations in ICH E6(R3) and ICH E8(R1):
Quality should be proactive, risk-informed, and documented in a way that is traceable.
This aligns directly with the expectations in ICH E6(R3) and ICH E8(R1):
Quality should be proactive, risk-informed, and documented in a way that is traceable.
Our MyRBQM Portal helps teams:
The result is not just cost savings, it’s greater predictability.
Poor quality is expensive but preventable. The earlier organizations identify what truly matters and align oversight to those priorities, the fewer costly disruptions they experience.
Quality is not an audit outcome.
It is a design choice.
Apply QbD and RBQM principles with configurable risk assessments, CtQ alignment, automated audit trails, and centralized monitoring insights.
Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.
Featured Insights
Start Your Roll-Out
Quick Answers
